RT Journal Article
T1 Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
A1 Boyero, Laura
A1 Sánchez-Gastaldo, Amparo
A1 Alonso, Miriam
A1 Noguera-Uclés, José Francisco
A1 Molina-Pinelo, Sonia
A1 Bernabé-Caro, Reyes
K1 NSCLC
K1 PD-1/PD-L1
K1 SCLC
K1 immune checkpoint inhibitors
K1 immunotherapy
K1 lung cancer
K1 monoclonal antibodies
K1 resistance mechanisms
AB After several decades without maintained responses or long-term survival of patients with lung cancer, novel therapies have emerged as a hopeful milestone in this research field. The appearance of immunotherapy, especially immune checkpoint inhibitors, has improved both the overall survival and quality of life of patients, many of whom are diagnosed late when classical treatments are ineffective. Despite these unprecedented results, a high percentage of patients do not respond initially to treatment or relapse after a period of response. This is due to resistance mechanisms, which require understanding in order to prevent them and develop strategies to overcome them and increase the number of patients who can benefit from immunotherapy. This review highlights the current knowledge of the mechanisms and their involvement in resistance to immunotherapy in lung cancer, such as aberrations in tumor neoantigen burden, effector T-cell infiltration in the tumor microenvironment (TME), epigenetic modulation, the transcriptional signature, signaling pathways, T-cell exhaustion, and the microbiome. Further research dissecting intratumor and host heterogeneity is necessary to provide answers regarding the immunotherapy response and develop more effective treatments for lung cancer.
SN 2072-6694
YR 2020
FD 2020-12-11
LK https://hdl.handle.net/10668/27496
UL https://hdl.handle.net/10668/27496
LA en
DS RISalud
RD Apr 17, 2025